Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | MC4R | P32245 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13365112 | 1.00 | PDE4B (0.60) | PDE4BRORCTACR1MC4RSLC6A2 | |
| SCHEMBL15397578 | 1.00 | PDE4B (0.60) | PDE4BRORCTACR1MC4RSLC6A2 | |
| SCHEMBL191321 | 1.00 | PDE4B (0.60) | PDE4BRORCTACR1MC4RSLC6A2 | |
| SCHEMBL191712 | 1.00 | PDE4B (0.60) | PDE4BRORCTACR1MC4RSLC6A2 | |
| SCHEMBL4159759 | 0.90 | PDE4B (0.52) | PDE4BRORCTACR1MC4RSLC6A2 | |
| SCHEMBL4141590 | 0.90 | PDE4B (0.52) | PDE4BRORCTACR1MC4RSLC6A2 | |
| SCHEMBL1972927 | 0.90 | PDE4B (0.52) | PDE4BRORCTACR1MC4RSLC6A2 | |
| SCHEMBL13365094 | 0.89 | PDE4B (0.62) | PDE4BRORCTACR1MC4RSLC6A2 | |
| SCHEMBL193015 | 0.88 | PDE4B (0.72) | PDE4BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL193014 | 0.88 | PDE4B (0.72) | PDE4BSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-2336105-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | PDE4B 3147/4885RORC 2859/4885TACR1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.